Insider Trading activities of Eyegate Pharmaceuticals Inc (EYEG)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eyegate Pharmaceuticals Inc (EYEG) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Eyegate Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Eyegate Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is EYEG. The reporting company's CIK number is 1372514.
The total value of stock buying since 2005 is $5,736,966.
The total value of stock sales since 2005 is $353,577.
The total value of stock option exercises since 2005 is $69,484.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Eyegate Pharmaceuticals Inc (EYEG).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2019-09 605,001 $945,651 0 $0 0 $0
2019-07 0 $0 205,367 $48,597 0 $0
2019-03 549,647 $87,607 0 $0 0 $0
2018-12 100,353 $13,532 0 $0 0 $0
2018-11 360,000 $54,226 0 $0 0 $0
2018-05 390,000 $65,696 0 $0 0 $0
2018-04 13,358,198 $1,658,382 0 $0 0 $0
2017-08 22,500 $22,875 0 $0 0 $0
2017-06 80,000 $0 0 $0 17,570 $11,420
2017-03 0 $0 13,338 $39,143 0 $0
2017-02 0 $0 0 $0 1,083 $1,841
2016-09 15,000 $22,335 0 $0 0 $0
2016-06 0 $0 83,939 $265,837 86,765 $56,223
2015-02 477,777 $2,866,662 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Eyegate Pharmaceuticals Inc insiders (EYEG)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2019-09-30 Boyd Steven Buy 5,001 1.57 7,851
2019-09-29 Boyd Steven Buy 600,000 1.56 937,800
2019-07-15 Romano Sarah (Chief Financial Officer) Sale 6,584 .23 1,534
2019-07-15 Wirostko Barbara (Chief Medical Officer) Sale 6,488 .23 1,511
2019-07-15 Mann Brenda (VP of Research & Development) Sale 6,350 .23 1,479
2019-07-15 Manzo Michael P. (VP of Engineering) Sale 6,584 .23 1,534
2019-07-15 From Stephen (President and CEO) Sale 42,452 .23 9,891
2019-07-12 Romano Sarah (Chief Financial Officer) Sale 6,583 .24 1,553
2019-07-12 Wirostko Barbara (Chief Medical Officer) Sale 6,488 .24 1,531
2019-07-12 Mann Brenda (VP of Research & Development) Sale 6,350 .24 1,498
2019-07-12 Manzo Michael P. (VP of Engineering) Sale 6,583 .24 1,553
2019-07-12 From Stephen (President and CEO) Sale 42,452 .24 10,018
2019-07-11 Romano Sarah (Chief Financial Officer) Sale 6,583 .24 1,586
2019-07-11 Wirostko Barbara (Chief Medical Officer) Sale 6,487 .24 1,563
2019-07-11 Mann Brenda (VP of Research & Development) Sale 6,349 .24 1,530
2019-07-11 Manzo Michael P. (VP of Engineering) Sale 6,583 .24 1,586
2019-07-11 From Stephen (President and CEO) Sale 42,451 .24 10,230
2019-03-29 Boyd Steven Buy 298,189 .15 46,219
2019-03-28 Boyd Steven Buy 130,811 .15 20,275
2019-03-27 Boyd Steven Buy 120,647 .17 21,113
2018-12-11 Boyd Steven Buy 30,953 .14 4,302
2018-12-10 Boyd Steven Buy 69,400 .13 9,230
2018-11-16 Boyd Steven Buy 178,136 .16 27,967
2018-11-15 Boyd Steven Buy 126,735 .14 18,376
2018-11-14 Boyd Steven Buy 55,129 .14 7,883
2018-05-29 Boyd Steven Buy 40,700 .19 7,773
2018-05-25 Boyd Steven Buy 17,575 .19 3,374
2018-05-18 Boyd Steven Buy 1,725 .18 319
2018-05-14 Boyd Steven Buy 15,758 .18 2,804
2018-05-11 Boyd Steven Buy 49,142 .18 8,796
2018-05-10 Boyd Steven Buy 23,917 .18 4,328
2018-05-09 Boyd Steven Buy 103,953 .17 17,152
2018-05-08 Boyd Steven Buy 37,230 .16 5,994
2018-05-07 Boyd Steven Buy 14,252 .16 2,294
2018-05-04 Boyd Steven Buy 85,748 .15 12,862
2018-04-20 Boyd Steven Buy 496,304 .18 87,349
2018-04-19 Boyd Steven Buy 1,256,920 .16 199,850
2018-04-18 Boyd Steven Buy 781,254 .16 123,438
2018-04-17 Garanzini Michael (Chief Commercial Officer) Buy 156,250 .00 0
2018-04-17 Boyd Steven Buy 1,895,610 .15 278,654
2018-04-17 Romano Sarah (Chief Financial Officer) Buy 62,500 .00 0
2018-04-17 From Stephen (President and CEO) Buy 125,000 .00 0
2018-04-16 Boyd Steven Buy 1,159,167 .12 144,895
2018-04-13 Boyd Steven Buy 7,425,193 .11 824,196
2017-08-15 Romano Sarah (Interim CFO) Buy 10,000 1.00 10,000
2017-08-10 From Stephen (President and CEO) Buy 12,500 1.03 12,875
2017-06-14 Romano Sarah (Interim CFO) Buy 20,000 .00 0
2017-06-14 From Stephen (President and CEO) Buy 60,000 .00 0
2017-06-02 Chaney Paul G Option Ex 17,570 .65 11,420
2017-03-13 Ventech Capital Ii Sale 4,419 2.80 12,386
2017-03-06 Goldberg Morton Sale 8,919 3.00 26,757
2017-02-27 Goldberg Morton Option Ex 1,083 1.70 1,841
2016-09-15 From Stephen (President and CEO) Buy 15,000 1.49 22,335
2016-06-30 From Stephen (President and CEO) Option Ex 52,990 .65 34,337
2016-06-15 Goldberg Morton Sale 15,000 3.16 47,355
2016-06-10 Ventech Capital Ii Sale 15,433 3.00 46,329
2016-06-09 Ventech Capital Ii Sale 13,167 3.08 40,528
2016-06-08 Ventech Capital Ii Sale 2,400 3.20 7,680
2016-06-07 Goldberg Morton Sale 746 3.31 2,472
2016-06-07 Ventech Capital Ii Sale 17,000 3.24 55,063
2016-06-06 Goldberg Morton Sale 5,543 3.25 18,042
2016-06-06 Ventech Capital Ii Sale 10,000 3.27 32,679
2016-06-03 Goldberg Morton Sale 4,650 3.37 15,689
2016-06-03 Goldberg Morton Option Ex 33,775 .65 21,886
2015-02-19 Ipsa (innoven Partenaires S.a.) Buy 366,667 6.00 2,200,002
2015-02-19 Ventech Capital Ii Buy 102,777 6.00 616,662
2015-02-19 Chaney Paul G Buy 8,333 6.00 49,998

Insider trading activities including stock purchases, stock sales, and option exercises of EYEG listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Eyegate Pharmaceuticals Inc (symbol EYEG, CIK number 1372514) see the Securities and Exchange Commission (SEC) website.




Real-time Insider Trading

Insider Officer Cluster Trading

Top Officer Buys of the Week

Top Officer Buys of the Month